drugset / Trial / NCT03405870

LIPIDS-P Trial Phase I/II Trial

NCT03405870 ↗

Phase 1/2 Completed 59 enrolled University of Florida
RandomizedParallel-groupSingle-blindTreatment

Summary

Briefly, this pilot clinical trial will evaluate preliminary safety and efficacy of the study drug (Smoflipid) at elevating cholesterol levels (primary outcome) in patients with sepsis and moderate organ dysfunction and will also evaluate measures of organ dysfunction, mortality, and biological activity (secondary outcomes).

Timeline

Start
2018-08-17
Primary completion
2023-04-26
Completion
2023-04-26

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper Administration of IV lipid emulsion to early sepsis patients with low cholesterol levels did not influence change in cholesterol levels from enrollment to 48 hours. PMID 38488429 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject SMOFlipid Other / unclassified 1 g/kg Intravenous
Subject SMOFlipid Other / unclassified 1.2 g/kg Intravenous
Subject SMOFlipid Other / unclassified 1.4 g/kg Intravenous
Subject SMOFlipid Other / unclassified 1.6 g/kg Intravenous